TNF and breast carcinoma: The clinical trial also identified a significant reduction in serum TNF-α levels in breast cancer patients (pre-PBMT = 82.13 ± 14.54 pg/mL; post-PBMT = 17.05 ± 2.267 pg/mL; p = 0.0045).